Anika Therapeutics, Inc. (ANIK)

Market Cap	131.20M
Revenue (ttm)	114.55M
Net Income (ttm)	-60.63M
Shares Out	14.42M
EPS (ttm)	-4.18
PE Ratio	n/a
Forward PE	218.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	204,657
Open	8.91
Previous Close	8.72
Day's Range	8.91 - 9.19
52-Week Range	7.87 - 26.99
Beta	0.64
Analysts	Buy
Price Target	15.00 (+64.84%)
Earnings Date	Jul 30, 2025

About ANIK

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Apr 29, 1993
• Employees: 288
• Stock Exchange: NASDAQ
• Ticker Symbol: ANIK
• Website: https://www.anika.com

Financial Performance

In 2024, Anika Therapeutics's revenue was $119.91 million, a decrease of -0.73% compared to the previous year's $120.79 million. Losses were -$56.39 million, -31.79% less than in 2023.

Analyst Forecast

According to one analyst, the rating for ANIK stock is "Buy" and the 12-month stock price target is $15.0.

Price Target

$15.0

(64.84% upside)

Analyst Consensus: Buy